If initial treatment for dyspepsia with either a PPI or ‘test and treat’ approach fails, the other approach should be tried next. NICE guidelines recommend prescribing a full-dose PPI for 1 month or testing for H. pylori infection and prescribing eradication therapy if positive. If symptoms persist, switch to the alternative strategy. Referral for routine upper GI endoscopy is not indicated at this stage.

Management of Dyspepsia and Referral for Possible Cancer

Dyspepsia is a common symptom that can be caused by various factors, including medication and lifestyle choices. However, it can also be a sign of underlying conditions such as stomach or oesophageal cancer. The 2015 NICE guidelines provide updated advice on when urgent referral for endoscopy is necessary. Patients with dysphagia or an upper abdominal mass consistent with stomach cancer should be referred urgently. Patients aged 55 years or older with weight loss and upper abdominal pain, reflux, or dyspepsia should also be referred urgently. Non-urgent referrals include patients with haematemesis or those with treatment-resistant dyspepsia, upper abdominal pain with low haemoglobin levels, or raised platelet count with other symptoms.

For patients with undiagnosed dyspepsia, a step-wise approach is recommended. First, medications should be reviewed for possible causes. Lifestyle advice should also be given. If symptoms persist, a trial of full-dose proton pump inhibitor for one month or a ‘test and treat’ approach for H. pylori can be tried. If symptoms persist after either approach, the alternative should be attempted. Testing for H. pylori infection can be done using a carbon-13 urea breath test, stool antigen test, or laboratory-based serology. If symptoms resolve following test and treat, there is no need to check for H. pylori eradication. However, if repeat testing is required, a carbon-13 urea breath test should be used.

Widespread convulsions without loss of consciousness may indicate a psychogenic non-epileptic seizure (pseudoseizure), especially in a patient with psychiatric comorbidities. A focal aware seizure would not involve whole-body convulsions, while an alcohol withdrawal seizure would involve loss of consciousness. A panic attack may involve involuntary movement, but widespread convulsions would be unusual.

Understanding Psychogenic Non-Epileptic Seizures

Psychogenic non-epileptic seizures, also known as pseudoseizures, are a type of seizure that is not caused by abnormal electrical activity in the brain. Instead, they are believed to be caused by psychological factors such as stress, trauma, or anxiety. These seizures can be difficult to diagnose as they often mimic true epileptic seizures, but there are certain factors that can help differentiate between the two.

Factors that may indicate pseudoseizures include pelvic thrusting, a family history of epilepsy, a higher incidence in females, crying after the seizure, and the seizures not occurring when the individual is alone. On the other hand, factors that may indicate true epileptic seizures include tongue biting and a raised serum prolactin level.

Video telemetry is a useful tool for differentiating between the two types of seizures. It involves monitoring the individual’s brain activity and behavior during a seizure, which can help determine whether it is caused by abnormal electrical activity in the brain or psychological factors.

It is important to accurately diagnose and treat psychogenic non-epileptic seizures as they can have a significant impact on an individual’s quality of life. Treatment may involve therapy to address underlying psychological factors, as well as medication to manage any associated symptoms such as anxiety or depression.

Controlled hyperventilation can be employed for patients with elevated ICP by increasing CO2 expiration. This leads to constriction of cerebral arteries due to low blood CO2 levels. As a result, blood flow decreases, reducing the volume inside the cranium and ultimately lowering intracranial pressure. Therefore, the other options are incorrect.

Understanding Raised Intracranial Pressure

As the brain and ventricles are enclosed by a rigid skull, any additional volume such as haematoma, tumour, or excessive cerebrospinal fluid (CSF) can lead to a rise in intracranial pressure (ICP). In adults, the normal ICP is between 7-15 mmHg in the supine position. The net pressure gradient causing cerebral blood flow to the brain is known as cerebral perfusion pressure (CPP), which can be calculated by subtracting ICP from mean arterial pressure.

Raised intracranial pressure can be caused by various factors such as idiopathic intracranial hypertension, traumatic head injuries, infections, meningitis, tumours, and hydrocephalus. Its symptoms include headache, vomiting, reduced levels of consciousness, papilloedema, and Cushing’s triad, which is characterized by widening pulse pressure, bradycardia, and irregular breathing.

To investigate the underlying cause, neuroimaging such as CT or MRI is key. Invasive ICP monitoring can also be done by placing a catheter into the lateral ventricles of the brain to monitor the pressure, collect CSF samples, and drain small amounts of CSF to reduce the pressure. A cut-off of >20 mmHg is often used to determine if further treatment is needed to reduce the ICP.

Management of raised intracranial pressure involves investigating and treating the underlying cause, head elevation to 30º, IV mannitol as an osmotic diuretic, controlled hyperventilation to reduce pCO2 and vasoconstriction of the cerebral arteries, and removal of CSF through techniques such as drain from intraventricular monitor, repeated lumbar puncture, or ventriculoperitoneal shunt for hydrocephalus.

Acute kidney injury (AKI) is a condition where there is a sudden decrease in kidney function, which can be defined by a decrease in glomerular filtration rate (GFR) or a decrease in urine output. AKI can be caused by various factors such as prerenal, renal, or postrenal causes. Medications can also cause AKI, and caution should be taken when prescribing ACE inhibitors to patients with declining renal function. In the event of an AKI, certain medications such as ACE inhibitors, A2RBs, NSAIDs, diuretics, aminoglycosides, metformin, and lithium should be temporarily discontinued. Atorvastatin and bisoprolol are safe to prescribe in patients with kidney disease, while finasteride and tamsulosin can be prescribed for benign prostatic hyperplasia but should be used with caution in patients with poor renal function.

Understanding Acute Kidney Injury: A Basic Overview

Acute kidney injury (AKI) is a condition where the kidneys experience a reduction in function due to an insult. In the past, the kidneys were often neglected in acute medicine, resulting in slow recognition and limited action. However, around 15% of patients admitted to the hospital develop AKI. While most patients recover their renal function, some may have long-term impaired kidney function due to AKI, which can result in acute complications, including death. Identifying patients at increased risk of AKI is crucial in reducing its incidence. Risk factors for AKI include chronic kidney disease, other organ failure/chronic disease, a history of AKI, and the use of drugs with nephrotoxic potential.

AKI has three main causes: prerenal, intrinsic, and postrenal. Prerenal causes are due to a lack of blood flow to the kidneys, while intrinsic causes relate to intrinsic damage to the kidneys themselves. Postrenal causes occur when there is an obstruction to the urine coming from the kidneys. Symptoms of AKI include reduced urine output, fluid overload, arrhythmias, and features of uraemia. Diagnosis of AKI is made through blood tests, urinalysis, and imaging.

The management of AKI is largely supportive, with careful fluid balance and medication review being crucial. Loop diuretics and low-dose dopamine are not recommended, but hyperkalaemia needs prompt treatment to avoid life-threatening arrhythmias. Renal replacement therapy may be necessary in severe cases. Prompt review by a urologist is required for patients with suspected AKI secondary to urinary obstruction, while specialist input from a nephrologist is necessary for cases where the cause is unknown or the AKI is severe.

Gallstones: Symptoms, Diagnosis, and Treatment

Gallstones are a common condition, with up to 24% of women and 12% of men affected. Local infection and cholecystitis may develop in up to 30% of cases, and 12% of patients undergoing surgery will have stones in the common bile duct. The majority of gallstones are of mixed composition, with pure cholesterol stones accounting for 20% of cases. Symptoms typically include colicky right upper quadrant pain that worsens after fatty meals. Diagnosis involves abdominal ultrasound and liver function tests, with magnetic resonance cholangiography or intraoperative imaging used to confirm the presence of stones in the bile duct. Treatment options include expectant management for asymptomatic gallstones, laparoscopic cholecystectomy for symptomatic gallstones, and early ERCP or surgical exploration for stones in the bile duct. Intraoperative cholangiography or laparoscopic ultrasound may be used to confirm anatomy or exclude CBD stones during surgery. ERCP carries risks such as bleeding, duodenal perforation, cholangitis, and pancreatitis.

After experiencing their first seizure, individuals must wait for a period of 6 months without any further seizures before they can apply to the DVLA to have their license reinstated. However, if they have been diagnosed with epilepsy, they must wait for a minimum of 12 months without any seizures before reapplying to the DVLA for their license to be reissued. It is crucial to understand that it is the patient’s responsibility to inform the DVLA and they should not drive until they have received permission from the DVLA. It is important to note that the medical team is not responsible for informing the DVLA. It is essential to keep in mind that the requirements may differ if the individual intends to drive a public or heavy goods vehicle.

The DVLA has guidelines for drivers with neurological disorders. Those with epilepsy/seizures must not drive and must inform the DVLA. The length of time off driving varies depending on the type and frequency of seizures. Those with syncope may need time off driving depending on the cause and number of episodes. Those with other conditions such as stroke, craniotomy, pituitary tumor, narcolepsy/cataplexy, and chronic neurological disorders should inform the DVLA and may need time off driving.

Pregnant women should avoid taking ACE inhibitors like ramipril as they can lead to fetal abnormalities and renal failure. These medications are believed to hinder the production of fetal urine, resulting in oligohydramnios, and increase the likelihood of cranial and cardiac defects. However, other drugs do not pose any known risks during pregnancy and can be continued if necessary.

Angiotensin-converting enzyme (ACE) inhibitors are commonly used as the first-line treatment for hypertension and heart failure in younger patients. However, they may not be as effective in treating hypertensive Afro-Caribbean patients. These inhibitors are also used to treat diabetic nephropathy and for secondary prevention of ischaemic heart disease. The mechanism of action of ACE inhibitors is to inhibit the conversion of angiotensin I to angiotensin II. They are metabolized in the liver through phase 1 metabolism.

ACE inhibitors may cause side effects such as cough, which occurs in around 15% of patients and may occur up to a year after starting treatment. This is thought to be due to increased bradykinin levels. Angioedema may also occur up to a year after starting treatment. Hyperkalaemia and first-dose hypotension are other potential side effects, especially in patients taking diuretics. ACE inhibitors should be avoided during pregnancy and breastfeeding, and caution should be exercised in patients with renovascular disease, aortic stenosis, or hereditary or idiopathic angioedema.

Patients receiving high-dose diuretic therapy (more than 80 mg of furosemide a day) are at an increased risk of hypotension when taking ACE inhibitors. Before initiating treatment, urea and electrolytes should be checked, and after increasing the dose, a rise in creatinine and potassium may be expected. Acceptable changes include an increase in serum creatinine up to 30% from baseline and an increase in potassium up to 5.5 mmol/l. Patients with undiagnosed bilateral renal artery stenosis may experience significant renal impairment. The current NICE guidelines provide a flow chart for the management of hypertension.

Sarcoidosis is the probable diagnosis based on the presence of erythema nodosum, a non-productive cough, arthralgia, and bilateral hilar lymphadenopathy on chest x-ray. This condition is known to cause hypercalcaemia due to the macrophages inside the granulomas, which increase the conversion of vitamin D to its active form. However, sarcoidosis is not typically associated with hyperkalaemia, hyponatraemia, megaloblastic anaemia, or thrombocytopenia.

Investigating Sarcoidosis

Sarcoidosis is a disease that does not have a single diagnostic test, and therefore, diagnosis is mainly based on clinical observations. Although ACE levels may be used to monitor disease activity, they are not reliable in diagnosing sarcoidosis due to their low sensitivity and specificity. Routine blood tests may show hypercalcemia and a raised ESR. A chest x-ray is a common investigation that may reveal different stages of sarcoidosis, ranging from normal (stage 0) to diffuse fibrosis (stage 4). Other investigations, such as spirometry and tissue biopsy, may also be used to diagnose sarcoidosis. However, the Kveim test, which involves injecting part of the spleen from a patient with known sarcoidosis under the skin, is no longer performed due to concerns about cross-infection.

CT scans may also be used to investigate sarcoidosis, as they can reveal nodularity and patchy areas of consolidation, particularly in the upper lobes of the lungs. It is important to note that sarcoidosis predominantly affects the upper zones of the lungs, unlike other pulmonary fibrosis conditions that affect the lower zones. Overall, a combination of clinical observations and investigations is necessary to diagnose sarcoidosis accurately.

When a patient with an acute exacerbation of COPD shows signs of respiratory acidosis (PaCO2>6 kPa, pH <7.35 ≥7.26) that persist despite immediate maximum standard medical treatment, it is recommended to consider the use of non-invasive ventilation (NIV). This is particularly important in cases where the patient is severely ill, as in the case of this patient with an infectious exacerbation of COPD. The British Thoracic Society guidelines suggest that NIV should be considered after maximal medical therapy, which in this case includes nebulisers, steroids, and theophylline. While there are other concerning features of this patient's condition, the PaCO2 and pH levels are the key indicators for the use of NIV. Guidelines for Non-Invasive Ventilation in Acute Respiratory Failure The British Thoracic Society (BTS) and the Royal College of Physicians have published guidelines for the use of non-invasive ventilation (NIV) in acute respiratory failure. NIV can be used in patients with COPD and respiratory acidosis with a pH of 7.25-7.35. However, patients with a pH lower than 7.25 require greater monitoring and a lower threshold for intubation and ventilation. NIV is also recommended for type II respiratory failure due to chest wall deformity, neuromuscular disease, or obstructive sleep apnea, as well as for cardiogenic pulmonary edema unresponsive to continuous positive airway pressure (CPAP) and weaning from tracheal intubation. For patients with COPD, the recommended initial settings for bi-level pressure support include an expiratory positive airway pressure (EPAP) of 4-5 cm H2O, an inspiratory positive airway pressure (IPAP) of 10-15 cm H2O, a back-up rate of 15 breaths/min, and a back-up inspiration-to-expiration ratio of 1:3. These guidelines aim to improve patient outcomes and reduce the need for invasive mechanical ventilation.

The most common cause of infective endocarditis is Staphylococcus aureus, especially in acute presentations and among intravenous drug users. However, if the patient has undergone valve replacement surgery more than 2 months ago, the spectrum of organisms causing endocarditis returns to normal, making Staphylococcus epidermidis less likely. While Streptococcus bovis can also cause endocarditis, it is not as common as Staphylococcus aureus and is associated with colon cancer. Staphylococcus epidermidis is the most common cause of endocarditis within 2 months post-valvular surgery. On the other hand, Streptococcus mitis, a viridans streptococcus found in the mouth, is associated with endocarditis following dental procedures or in patients with poor dental hygiene.

Aetiology of Infective Endocarditis

Infective endocarditis is a condition that affects patients with previously normal valves, rheumatic valve disease, prosthetic valves, congenital heart defects, intravenous drug users, and those who have recently undergone piercings. The strongest risk factor for developing infective endocarditis is a previous episode of the condition. The mitral valve is the most commonly affected valve.

The most common cause of infective endocarditis is Staphylococcus aureus, particularly in acute presentations and intravenous drug users. Historically, Streptococcus viridans was the most common cause, but this is no longer the case except in developing countries. Streptococcus mitis and Streptococcus sanguinis are the two most notable viridans streptococci, commonly found in the mouth and dental plaque. Coagulase-negative Staphylococci such as Staphylococcus epidermidis are the most common cause of endocarditis in patients following prosthetic valve surgery.

Streptococcus bovis is associated with colorectal cancer, with the subtype Streptococcus gallolyticus being most linked to the condition. Non-infective causes of endocarditis include systemic lupus erythematosus and malignancy. Culture negative causes may be due to prior antibiotic therapy or infections caused by Coxiella burnetii, Bartonella, Brucella, or HACEK organisms (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella).